2. Disease Areas
  3. Respiratory Disease
  4. Lower Respiratory Inflammation

Lower Respiratory Inflammation

Lower respiratory inflammation is commonly triggered by infections such as bronchitis, bronchiolitis, or pneumonia, resulting in symptoms including cough, shortness of breath, chest pain, and fatigue.

 

Lower Respiratory Inflammation (58):

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-142021
    Z-Leu-Arg-AMC 156192-32-4 99.24%
    Z-Leu-Arg-AMC is a fluorogenic peptide substrate for cysteine proteases (e.g., Cathepsin) (Ex=350 nm，Em=460 nm). Z-Leu-Arg-AMC is preferentially cleaved by Cathepsin K and S under weakly acidic conditions, while its hydrolysis relies on residual Cathepsin S activity at neutral pH. Z-Leu-Arg-AMC serves as a substrate for recombinant Sphenophorus levis Cathepsin L, falcipain-2, falcipain-3, berghepain-2, knowlepain-2, vivapain-2, as well as falcipain-2 chimeras and constructs. It enables quantitative detection of cysteine protease activity in human inflammatory bronchoalveolar lavage fluid via fluorescence generation. Z-Leu-Arg-AMC can be used in research related to pulmonary inflammatory diseases and malaria.
    Z-Leu-Arg-AMC
  • HY-N0732
    Jolkinolide B 37905-08-1 99.65%
    Jolkinolide B is a bioactive diterpene isolated from the roots of Euphorbia fischeriana Steud with oral activity. Jolkinolide B downregulates XIAP, cIAP1, cIAP2, and phosphorylated Akt, upregulates Smac, activates caspase-3 and caspase-9, and inhibits NF-κB, TGFβ/smad3 and JAK/STAT3 pathways. Jolkinolide B exerts comprehensive biological effects including inducing cancer cell apoptosis, suppressing inflammatory responses, improving lung function, alleviating hepatic steatosis and eliminating intracellular Mycobacterium tuberculosis. Jolkinolide B can be used for the research of leukemia, histiocytic lymphoma, asthma, metabolic dysfunction-associated steatotic liver disease and tuberculosis.
    Jolkinolide B
  • HY-N3519
    Platycodin D3 67884-03-1 98.91%
    Platycodin D3 is a triterpenoid saponin that can be found in Platycodon grandiflorum. Platycodin D3 exhibits multiple activities including anti-inflammation, regulation of airway mucus secretion, improvement of asthmatic airway inflammation and remodeling, and inhibition of hepatitis C virus (HCV) replication. The IC50 value of Platycodin D3 against HCV NS5B RNA-dependent RNA polymerase is 8 μg/mL. Platycodin D3 can be used in studies related to asthma, hepatitis C virus infection and inflammatory diseases.
    Platycodin D3
  • HY-157536
    SMT-738 2862851-15-6 98.47%
    SMT-738 is a bacterial bactericide. SMT-738 targets the small molecules responsible for lipoprotein transport in Enterobacteriaceae, causing abnormal lipoprotein localization and bacterial cell death. SMT-738 inhibits the growth of E. coli and K. pneumoniae. SMT-738 reduces bacterial loads in mouse models of urinary tract infection, bloodstream infection, and pulmonary infection caused by Enterobacterales. SMT-738 can be used in the research of Enterobacteriaceae infections, urinary tract infections, bloodstream infections, and pneumonia.
    SMT-738
  • HY-Y1366
    Hydroxyacetone 116-09-6 98.93%
    Hydroxyacetone is a toxic compound. Hydroxyacetone can be isolated from e-cigarette aerosols. Hydroxyacetone reduces the activity of cellular Mitochondrial reductase (with an IC50 of 5.53 mg/mL for mitochondrial reductase in BEAS-2B cells) and increases ROS levels. Hydroxyacetone induces mitochondrial stress and oxidative damage. Hydroxyacetone induces destabilization of F-actin. At high concentrations, Hydroxyacetone promotes cell rounding and Apoptotic body formation. Hydroxyacetone exerts toxic effects on cells including airway epithelial cells and possesses respiratory toxicity potential.\n
    Hydroxyacetone
  • HY-P992034
    APG808
    APG808 (PR001) is an anti-human IL-4Rα monoclonal antibody. APG808 binds to IL-4Rα, prevents IL-13Rα1/IL-4Rα heterodimer formation, and disrupts IL-13 and IL-4 mediated signaling. APG808 ablates Fc and complement effector functions. APG808 can be used for the research of chronic obstructive pulmonary disease, asthma, atopic dermatitis.
    APG808
  • HY-183885
    MPI3 890648-84-7
    MPI3 is a reversible covalent SARS-CoV-2 MPro inhibitor with an enzymatic IC50 of 8.5 nM. MPI3 can be used for the research of covid-19.
    MPI3
  • HY-19653A
    Butixocort propionate 98449-05-9
    Butixocort propionate (JO 1222), a corticosteroid, is a potent Glucocorticoid Receptor agonist. Butixocort propionate exhibits anti-inflammatory activity. Butixocort propionate can be used for the researches of inflammation, immunology and metabolic disease, such as asthma and arthritis.
    Butixocort propionate
  • HY-135490
    Reproterol 54063-54-6 98.94%
    Reproterol is a selective β2-adrenoceptor agonist and cAMP phosphodiesterase (PDE) inhibitor. Reproterol inhibits adenylate cyclase-induced phosphodiesterase activity. Reproterol inhibits histamine release from mast cells. Reproterol is applicable to research related to asthma.
    Reproterol
  • HY-114495
    Caerulomycin A 21802-37-9 98.0%
    Caerulomycin A is an orally active immunomodulator and antimicrobial agent. Caerulomycin A targets Smad3, STAT1 and GATA-3. Caerulomycin A downregulates GATA-3 expression, inhibits Th2 cell differentiation and Th2 cytokine production, reduces IgE levels, and alleviates pulmonary inflammatory responses and eosinophil infiltration. Caerulomycin A ameliorates collagen-induced arthritis symptoms, reduces joint inflammation and synovitis, and decreases the levels of proinflammatory cytokines in joints. Caerulomycin A inhibits the growth of some filamentous fungi, yeasts and specific bacteria. Caerulomycin A can be used in research related to arthritis and asthma.
    Caerulomycin A
  • HY-A0130
    Sulfalene 152-47-6 99.73%
    Sulfalene (Sulfametopyrazine) is an orally active antimalarial agent. Sulfalene competes with para-aminobenzoic acid in plasmodial and bacterial folic acid synthesis pathways. Sulfalene reduces trachoma-associated pathological changes. Sulfalene can be used for the research of acute falciparum malaria, Schistosoma mansoni infection, trachoma, chronic bronchitis, and bacteriuria in pregnancy.
    Sulfalene
  • HY-P2866
    β-N-Acetylhexosaminidase, Streptococcus pneumoniae 9012-33-3
    β-N-Acetylhexosaminidase, Streptococcus pneumoniae is a cell surface virulence factor of Streptococcus pneumoniae, which contains two synergistically acting GH20 domains (with higher activity in GH20-2). β-N-Acetylhexosaminidase, Streptococcus pneumoniae specifically recognizes and hydrolyzes substrates with β(1,2) glycosidic bonds via Trp-443 and Tyr-482 residues. β-N-Acetylhexosaminidase, Streptococcus pneumoniae catalyzes the hydrolysis of β(1,2)-linked N-acetylglucosamine groups and related disaccharides, and promotes persistent colonization of bacteria in the airway by modifying host defense molecules and releasing monosaccharides for bacterial growth. β-N-Acetylhexosaminidase, Streptococcus pneumoniae can be used in studies related to Streptococcus pneumoniae infection, acute pneumonia, otitis media and meningitis.
    β-N-Acetylhexosaminidase, Streptococcus pneumoniae
  • HY-18706
    trans-Tranilast 70806-55-2 99.63%
    trans-Tranilast (trans-MK-341) is an isomer of Tranilast (HY-B0195), and an anti-allergy agent used in studies of bronchial asthma, allergic rhinitis, and atopic dermatitis.
    trans-Tranilast
  • HY-P1111
    Lyn peptide inhibitor 222018-18-0 99.35%
    Lyn peptide inhibitor (YGYRLRRKWEEKIPNP-NH2) is a potent, cell-permeable Lyn kinase inhibitor that inhibits Lyn-coupled signaling pathways associated with the IL-5 receptor while preserving the integrity of other signals. Lyn peptide inhibitor blocks the activation of Lyn and inhibits the binding of Lyn tyrosine kinase to the βc subunit of the IL-3/GM-CSF/IL-5 receptor. Lyn peptide inhibitor can be used in the research of eosinophilic diseases such as asthma and allergy.
    Lyn peptide inhibitor
  • HY-P99417
    Abrezekimab 2043952-59-4
    Abrezekimab (UCB4144; VR 942) is a humanized, high-affinity, neutralizing anti-human-IL-13 antibody fragment that binds to IL-13. Abrezekimab prevents IL-13 binding to the IL-13 Rα1 subunit. Abrezekimab can be used for the research of asthma.
    Abrezekimab
  • HY-P991278
    ABM-125
    ABM-125 is a IL-25 neutralizer and immune response modulator. ABM-125 neutralizes human and mouse IL-25 and blocks type 2 immune activation function. ABM-125 regulates virus-induced inflammatory cytokine expression and increases the expression level of antiviral interferons in rhinovirus-infected asthmatic bronchial epithelial cells. For the isotype control of ABM-125, refer to Human IgG1 kappa, Isotype Control (HY-P99001). ABM-125 is applicable to research related to virus-induced acute asthma exacerbations.
    ABM-125
  • HY-159536
    Frevecitinib 1299417-07-4
    Frevecitinib (KN-002) is a potent pan-JAK inhibitor (i.e. JAK1, JAK2, JAK3, TYK2). Frevecitinib can be used for the study of asthma and other respiratory conditions such as chronic obstructive pulmonary disease (COPD).
    Frevecitinib
  • HY-177063
    IL-6-IN-2 296790-70-0 99.95%
    IL-6-IN-2 is an interleukin-6 (IL-6) inhibitor. IL-6-IN-2 binds to IL-6 at Lys66, Phe74, Gln175, Ser176, and Arg179 via π-π, π-alkyl, hydrogen bond, and hydrophobic interactions to block IL-6/IL-6R heterocomplex formation. IL-6-IN-2 exhibits low gastrointestinal absorption rate. IL-6-IN-2 can be used for the research of cytokine release syndrome, covid-19.
    IL-6-IN-2
  • HY-163101
    CP-96021 139401-43-7 98.04%
    CP-96021 is an orally active dual leukotriene D4 (LTD4) and platelet activating factor (PAF) receptor antagonist, featuring a guinea pig LTD4 receptor Ki of 34 nM and a rabbit PAF receptor Ki of 37 nM. CP-96021 blocks ligand binding to its target receptors, inhibits ligand-induced bronchoconstriction, and inhibits antigen-triggered airway obstructive effects. CP-96021 can be used for the research of asthma.
    CP-96021
  • HY-P992447
    QX008N
    QX008N is a humanized IgG1 monoclonal antibody and also a TSLP inhibitor with a KD value of 0.0175 nM. QX008N blocks TSLP-induced signaling pathways by inhibiting the interaction of TSLP-TSLPR-IL-7Rα. QX008N reduces eosinophil and IgE levels, improves pulmonary function, blocks TSLP-induced inflammation, and enhances the inhibitory effect on inflammatory mediators when administered in combination with anti-IL-4R antibodies. QX008N is applicable to relevant research on asthma.
    QX008N